<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858558</url>
  </required_header>
  <id_info>
    <org_study_id>J1343</org_study_id>
    <secondary_id>NA_00084466</secondary_id>
    <nct_id>NCT01858558</nct_id>
  </id_info>
  <brief_title>Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma</brief_title>
  <official_title>Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out if altering the immune system by giving activated
      marrow infiltrating lymphocytes (MILs) can improve outcomes for multiple myeloma patients who
      receive a standard autologous stem cell transplant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">June 19, 2019</completion_date>
  <primary_completion_date type="Actual">June 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of MILs as Assessed by the Ability to Harvest, Expand, and Infuse the MILs Product</measure>
    <time_frame>120 days</time_frame>
    <description>Feasibility is defined as the ability to harvest, expand, and infuse the MILs product within 120 days. After treating 60 patients with MILs, we will declare MILs not feasible if we can only harvest, expand, and deliver MILs to 40 or fewer patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Determined by Total Number of Grade 3 or Higher Adverse Events</measure>
    <time_frame>60 days from aMILs harvest until day 60 after transplant</time_frame>
    <description>Total number of adverse events grade 3 or higher that occur from MILs harvest through 60 days after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>OS assessed by number of participants alive at the end of follow up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Median PFS time equals the time of randomization (in months) until disease progression, death from any cause, or protocol deviation due to lenalidomide dosing (above 10mg), whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>aMIL Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No aMIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aMIL</intervention_name>
    <description>On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
    <arm_group_label>aMIL Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No aMIL</intervention_name>
    <description>On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.</description>
    <arm_group_label>No aMIL</arm_group_label>
    <arm_group_label>aMIL Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 80 years old;

          -  Patients with active myeloma requiring systemic treatment;

          -  Newly diagnosed patients. Relapsed myeloma patients that have not previously had a
             transplant;

          -  Meeting criteria for high-risk disease;

          -  Measurable serum and/or urine M-protein from prior to induction therapy documented and
             available. A positive serum free lite assay is acceptable;

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 (see Appendix
             C).

          -  Meet all institutional requirements for autologous stem cell transplantation;

          -  The patient must be able to comprehend and have signed the informed consent;

          -  Patients must have had &gt; than PR after last therapy.

        Exclusion Criteria:

          -  Diagnosis of any of the following cancers:

               -  POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,
                  endocrinopathy, monoclonal protein [M-protein] and skin changes);

               -  Non-secretory myeloma (no measurable protein on Serum Free Lite Assay);

               -  Plasma cell leukemia;

          -  Diagnosis of amyloidosis;

          -  Failed to achieve at least a partial response (PR) to latest therapy;

          -  Previous hematopoietic stem cell transplantation;Patients can have had prior relapsed
             disease as long as they have never been previously transplanted;

          -  Known history of HIV infection;

          -  Use of corticosteroids (glucocorticoids) within 21 days of bone marrow collection;

          -  Use of any myeloma-specific therapy within 21 days of bone marrow collection;

          -  Infection requiring treatment with antibiotics, antifungal, or antiviral agents within
             seven days of registration;

          -  Participation in any clinical trial within 28 days of registration on this trial,
             which involved an investigational drug or device;

          -  History of malignancy other than multiple myeloma within five years of registration,
             except adequately treated basal or squamous cell skin cancer;

          -  Active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic
             lupus erythematosis) requiring active systemic treatment. Hypothyroidism without
             evidence of Grave's disease or Hashimoto's thyroiditis is permitted.

          -  Human T-lymphotropic virus (HTLV) 1 or 2 positive;

          -  Known hypersensitivity to Prevnar or any of its components;

          -  Contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Imus, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <results_first_submitted>June 11, 2020</results_first_submitted>
  <results_first_submitted_qc>June 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2020</results_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT01858558/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at four sites: Johns Hopkins University, Moffitt Cancer Center, Mayo Clinic (Jacksonville) and the Blood and Marrow Transplant Group of Georgia (Northside).</recruitment_details>
      <pre_assignment_details>Of the 102 patients randomized, one was randomized to the control group who was lost to follow-up prior to start; did not have aMILs harvested, and was not transplanted. This patient is therefore not included in this report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aMIL Arm</title>
          <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
        </group>
        <group group_id="P2">
          <title>No aMIL</title>
          <description>Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
No aMIL: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Product contamination</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed expansion of cell product</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>aMIL Arm</title>
          <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
        </group>
        <group group_id="B2">
          <title>No aMIL</title>
          <description>Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
No aMIL: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" lower_limit="35.0" upper_limit="74.8"/>
                    <measurement group_id="B2" value="59.0" lower_limit="37.1" upper_limit="75.9"/>
                    <measurement group_id="B3" value="61.7" lower_limit="35.0" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Newly Diagnosed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Relapsed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myeloma Prognostic Risk Signature (MYPRS) Risk Category</title>
          <description>The Myeloma Prognostic Risk Signature (MyPRS®) (Signal Genetics™) is used to estimate the underlying activity of disease progression in patients diagnosed with active multiple myeloma.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>High Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>N/A</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indeterminate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>70-gene expression Prognostic Risk Score (GEP-70)</title>
          <description>The 70-gene Prognostic Risk Score (GEP-70) quantifies the expression of 70 genes commonly altered in multiple myeloma. Primarily prognostic, GEP-70 assesses risk of disease relapse and survival outcomes and is the randomization stratification of the MYPRS multiple myeloma specific gene expression profile risk categories.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not High Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>ECOG Scoring System
0= Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours
Capable of only limited self care, confined to bed or chair more than 50% of waking hours
Completely disabled. Cannot carry on any self care. Totally confined to bed or chair
Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 or 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Staging System (ISS) Multiple Myeloma Classification</title>
          <description>Prognosticates the severity of multiple myeloma and patient survival based on routinely obtained lab values.
Stage I= Serum β2 microglobulin &lt; 3.5 mg/l; serum albumin ≥ 3.5 g/dl; standard-risk chromosomal abnormalities (CA) and normal lactate dehydrogenase (LDH) Stage II= not stage I or Stage III Stage III= Serum β2 microglobulin ≥ 5.5 mg/L and either high-risk CA by florescent in situ hybridization (FISH) or high LDH</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Salmon Stage multiple myeloma classification</title>
          <description>demonstrates the correlation between the amount of myeloma and the damage it has caused based on number of bone lesions, anemia, serum calcium levels, and serum and urine light chain levels, and can be measured as myeloma cell mass (myeloma cells in billions/m2)* .
Stage I= low cell mass (600 billion) Stage II= intermediate cell mass (600-1200 billion) Stage III= high cell mass (&gt;1200 billion)
Subcategory:
A = normal renal function. B= abnormal renal function</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>IA-IB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIA-IIB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIIA-IIIB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior Multiple Myeloma Treatments</title>
          <units>prior treatments</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to Diagnosis</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.53" lower_limit="0.07" upper_limit="8.15"/>
                    <measurement group_id="B2" value="0.76" lower_limit="0.38" upper_limit="4.80"/>
                    <measurement group_id="B3" value="0.55" lower_limit="0.07" upper_limit="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to stem cell transplant (SCT)</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" lower_limit="35.0" upper_limit="403.0"/>
                    <measurement group_id="B2" value="56.0" lower_limit="33.0" upper_limit="246.0"/>
                    <measurement group_id="B3" value="60.0" lower_limit="33.0" upper_limit="403.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of MILs as Assessed by the Ability to Harvest, Expand, and Infuse the MILs Product</title>
        <description>Feasibility is defined as the ability to harvest, expand, and infuse the MILs product within 120 days. After treating 60 patients with MILs, we will declare MILs not feasible if we can only harvest, expand, and deliver MILs to 40 or fewer patients.</description>
        <time_frame>120 days</time_frame>
        <population>71 patients were evaluable in the feasibility set: 70 randomized to the aMILs Arm, plus one patient who was not randomized due to harvest failure.</population>
        <group_list>
          <group group_id="O1">
            <title>aMIL Arm</title>
            <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of MILs as Assessed by the Ability to Harvest, Expand, and Infuse the MILs Product</title>
          <description>Feasibility is defined as the ability to harvest, expand, and infuse the MILs product within 120 days. After treating 60 patients with MILs, we will declare MILs not feasible if we can only harvest, expand, and deliver MILs to 40 or fewer patients.</description>
          <population>71 patients were evaluable in the feasibility set: 70 randomized to the aMILs Arm, plus one patient who was not randomized due to harvest failure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number who received aMILS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feasible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason not feasible- failed harvest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason not feasible- disease progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason not feasible- death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason not feasible- lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason not feasible- failed expansion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason not feasible- cell product contamination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason not feasible- greater than 120 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Determined by Total Number of Grade 3 or Higher Adverse Events</title>
        <description>Total number of adverse events grade 3 or higher that occur from MILs harvest through 60 days after transplant.</description>
        <time_frame>60 days from aMILs harvest until day 60 after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aMIL Arm</title>
            <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
          </group>
          <group group_id="O2">
            <title>No aMIL</title>
            <description>Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
No aMIL: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity as Determined by Total Number of Grade 3 or Higher Adverse Events</title>
          <description>Total number of adverse events grade 3 or higher that occur from MILs harvest through 60 days after transplant.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS assessed by number of participants alive at the end of follow up period.</description>
        <time_frame>3 years</time_frame>
        <population>This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.</population>
        <group_list>
          <group group_id="O1">
            <title>aMIL Arm</title>
            <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS assessed by number of participants alive at the end of follow up period.</description>
          <population>This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Median PFS time equals the time of randomization (in months) until disease progression, death from any cause, or protocol deviation due to lenalidomide dosing (above 10mg), whichever occurs first.</description>
        <time_frame>5 years</time_frame>
        <population>This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.</population>
        <group_list>
          <group group_id="O1">
            <title>aMIL Arm</title>
            <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Median PFS time equals the time of randomization (in months) until disease progression, death from any cause, or protocol deviation due to lenalidomide dosing (above 10mg), whichever occurs first.</description>
          <population>This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.82" lower_limit="18.53" upper_limit="41.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 Days from aMILs harvest until Day 60 after transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>aMIL Arm</title>
          <description>Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.</description>
        </group>
        <group group_id="E2">
          <title>No aMIL</title>
          <description>Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
No aMIL: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 3 or higher Adverse Events (AEs) from aMILs harvest to 60 days following autologous stem cell transplant (ASCT)</description>
                <counts group_id="E1" events="45" subjects_affected="36" subjects_at_risk="70"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>lymphocyte count decreased</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>ventricular arrhythmia</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis infection</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>bacteremia</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>mucosal infection</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Scrotal Infection</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>renal calculi</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>thromboembolic event</sub_title>
                <description>Grade 3 or higher AEs from aMILs harvest to 60 days following ASCT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>infusion related reaction</sub_title>
                <description>63 participants in the aMILs Arm had infusions, of those, 8 had record of infusion reaction.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>manufacture failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>product contamination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Philip Imus, MD</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>410-955-8873</phone>
      <email>pimus1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

